Anika Therapeutics Inc (ANIK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.17 is considered Undervalued compared with the five-year average of 190.21. The fair price of Anika Therapeutics Inc (ANIK) is between 23.06 to 38.55 according to relative valuation method. Compared to the current price of 14.02 USD , Anika Therapeutics Inc By Undervalued By 39.19%.

Relative Value

Fair Zone

23.06-38.55

Current Price：14.02

39.19%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Anika Therapeutics Inc (ANIK) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Anika Therapeutics Inc (ANIK) has a current Price-to-Book (P/B) ratio of 0.92. Compared to its 3-year average P/B ratio of 1.37, the current P/B ratio is approximately -32.85% higher. Relative to its 5-year average P/B ratio of 1.49, the current P/B ratio is about -38.34% higher. Anika Therapeutics Inc (ANIK) has a Forward Free Cash Flow (FCF) yield of approximately 0.48%. Compared to its 3-year average FCF yield of -1.38%, the current FCF yield is approximately -134.72% lower. Relative to its 5-year average FCF yield of -0.50%, the current FCF yield is about -196.82% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ANIK competitors is 2.89, providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK.O) exhibits a P/S ratio of 1.17, which is -59.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ANIK increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ANIK in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ANIK currently overvalued or undervalued?

What is Anika Therapeutics Inc (ANIK) fair value?

ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Anika Therapeutics Inc (ANIK) is between 23.06 to 38.55 according to relative valuation method.

How does ANIK's valuation metrics compare to the industry average?

The average P/S ratio for ANIK's competitors is 2.89, providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK) exhibits a P/S ratio of 1.17, which is -59.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Anika Therapeutics Inc (ANIK) as of Mar 03 2026?

As of Mar 03 2026, Anika Therapeutics Inc (ANIK) has a P/B ratio of 0.92. This indicates that the market values ANIK at 0.92 times its book value.

What is the current FCF Yield for Anika Therapeutics Inc (ANIK) as of Mar 03 2026?

As of Mar 03 2026, Anika Therapeutics Inc (ANIK) has a FCF Yield of 0.48%. This means that for every dollar of Anika Therapeutics Inc's market capitalization, the company generates 0.48 cents in free cash flow.

What is the current Forward P/E ratio for Anika Therapeutics Inc (ANIK) as of Mar 03 2026?

As of Mar 03 2026, Anika Therapeutics Inc (ANIK) has a Forward P/E ratio of 51.94. This means the market is willing to pay $51.94 for every dollar of Anika Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Anika Therapeutics Inc (ANIK) as of Mar 03 2026?

As of Mar 03 2026, Anika Therapeutics Inc (ANIK) has a Forward P/S ratio of 1.17. This means the market is valuing ANIK at $1.17 for every dollar of expected revenue over the next 12 months.

ANIK Valuation